[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Definium Therapeutics US, Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":64},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,40],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100641561",false,"NCT07592689","A Phase 3 Trial of DT120 for Major Depressive Disorder (Ascend)","A Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled, 12-Week Study (Part A) With a 40-Week Open-label Extension (Part B) Evaluating the Efficacy and Safety of Oral DT120 Compared to Placebo in the Treatment of Adults With Major Depressive Disorder - Ascend","Inclusion Criteria:\n\n1. Diagnosis of MDD per DSM-5\n2. Male or female aged 18 to 74\n3. Currently experiencing a major depressive episode (MDE) of ≥8 weeks and ≤24 months duration\n4. MADRS Total Score ≥26\n5. CGI-S Score ≥4\n\nExclusion Criteria:\n\n1. Certain psychiatric disorders (other than major depressive disorder)\n2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder\n3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine\n4. Any clinically significant unstable illness","ALL","18 Years","74 Years",{"count":19,"type":20},165,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","A Phase 3 Double-blind, Placebo-controlled Study (Part A) with an Open-label Extension (Part B) Evaluating DT120 Compared to Placebo in Major Depressive Disorder - Ascend",[26],"Major Depressive Disorder","RECRUITING","2026-06-26",{"date":30,"type":31},"2026-06-29","ACTUAL",{"date":33,"type":31},"2026-05-10",{"date":35,"type":20},"2028-06",{"name":37,"class":38},"Definium Therapeutics US, Inc.","INDUSTRY",27,{"id":41,"slug":4,"hasResults":10,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":46,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":55,"lastUpdatePostDateStruct":56,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100616307","NCT07303907","A Phase 2A Trial of DT402 for Autism Spectrum Disorder","An Open-label Study Evaluating DT402 in Adults With Autism Spectrum Disorder","Inclusion Criteria:\n\n1. Diagnosis of ASD per records as confirmed by standard semi-structured interview for Autism diagnosis (eg, Autism Diagnostic Observation Schedule-Second Edition)\n2. Male or Female aged 18 to 65\n3. Presents with clinically significant deficits in socialization and communication as determined by Social Responsiveness Scales (SRS-2) ≥66\n\nExclusion Criteria:\n\n1. Has uncorrected abnormalities in eye movement, alignment, or acuity or atypical eye features that could interfere with eye tracking\n2. First degree relative with or lifetime history of a psychotic disorder or bipolar disorder\n3. Current diagnosis of alcohol or substance use disorder (excluding nicotine and caffeine)\n4. Any clinically significant unstable illness","65 Years",{"count":48,"type":20},20,[50],"PHASE2","A Phase 2A Trial of DT402 Open-Label Study in Adults with Autism Spectrum Disorder",[53,54],"Autism Spectrum Disorder","ASD","2026-03-31",{"date":57,"type":31},"2026-04-06",{"date":59,"type":31},"2025-12-03",{"date":61,"type":20},"2027-08",{"name":37,"class":38},1,""]